Skip to main content
SpringerLink
Log in

Naturalistic Treatment of Alzheimer’s Disease with Galantamine

12-Month Follow-Up from the NATURE Study

  • Correspondence
  • Published:
CNS Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Brodaty H, Woodward M, Boundy K, et al. A naturalistic study of galantamine for Alzheimer’s disease. CNS Drugs 2006; 20: 935–43

    Article  PubMed  CAS  Google Scholar 

  2. Raskind M, Peskind E, Truyen L, et al. The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Arch Neurol 2004; 61: 252–6

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors acknowledge the contribution of the NATURE investigators. In compliance with the Uniform Requirements for Manuscripts (URM), established by the International Committee of Medical Journal Editors, the sponsor of this study, Janssen-Cilag Pty Ltd, did not impose any impediment, directly or indirectly, on the publication of the results of the study. Professor Henry Brodaty, Associate Professor Michael Woodward and Dr Karyn Boundy are consultants, supported speakers and supported investigators for Janssen-Cilag Australia. Nicola Barnes is an employee of Janssen-Cilag Pty Ltd. Dr Peter Tobin (Janssen-Cilag Pty Ltd) provided editorial assistance.

Author information

Authors and Affiliations

  1. Academic Department for Old Age Psychiatry, School of Psychiatry, University of New South Wales and Prince of Wales Hospital, Randwick, New South Wales, Australia

    Henry Brodaty

  2. Austin Health, Heidelberg Repatriation Hospital, Heidelberg West, Victoria, Australia

    Michael Woodward

  3. Neurology Department, The Queen Elizabeth Hospital, Woodville South, South Australia, Australia

    Karyn Boundy

  4. Medical Research Department, Janssen-Cilag Pty Ltd, North Ryde, New South Wales, Australia

    Nicola Barnes

Authors
  1. Henry Brodaty
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Woodward
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Karyn Boundy
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nicola Barnes
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brodaty, H., Woodward, M., Boundy, K. et al. Naturalistic Treatment of Alzheimer’s Disease with Galantamine. CNS Drugs 21, 335–336 (2007). https://doi.org/10.2165/00023210-200721040-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-200721040-00006

Keywords

Search

Navigation